The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes
Authors' conclusion
Systemic exposure to oral enavogliflozin 0.5 mg was similar among the patients with T2DM regardless of their renal function levels. However, the glucosuric effect of enavogliflozin decreased with RI. Considering the UGE observed and approved therapeutic use of other SGLT2 inhibitors, the efficacy of enavogliflozin with regard to glycaemic control could be explored in patients with mild and moderate RI (estimated glomerular filtration rate ≥30 or ≥45 mL/min/1.73 m2) in a subsequent larger study.
Study context
- Population
- Patients with T2D stratified by renal function21 completed
- Comparison
- Enavogliflozin 0.5 mg pharmacokinetic (PK)/pharmacodynamic (PD) across renal function groups
- Outcome
- PK and PD vs creatinine clearance (CrCL)
Methodological detailstwo-part, stratified by renal function
- Two-part
- Stratified by renal function
Main finding
As reported in the abstract
Daily urinary glucose excretion positively correlated with creatinine clearance (CrCL) after single dose
r = 0.7866
p < 0.0001
Daily urinary glucose excretion positively correlated with CrCL after multiple doses
r = 0.6606
p = 0.0438
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →